Valerie G. Brunton

Prof. Valerie G. Brunton

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
LGLaura Gómez-Cuadrado
Laura Gómez-Cuadrado
NTNatasha Tracey
Natasha Tracey
RMRuoyu Ma
Ruoyu Ma
BQBinzhi Qian
Binzhi Qian
VBValerie G. Brunton
Valerie G. Brunton
Metastasis is the spread of cancer cells from a primary tumor to distant sites within the body to establish secondary tumors. Although this is an inefficient process, the consequences are devastating as metastatic disease accounts for >90% of cancer-related deaths. The formation of metastases is the result of a series of events that allow cancer cells to escape from the primary site, survive in the lymphatic system or blood vessels, extravasate and grow at distant sites. The metastatic capacity of a tumor is determined by genetic and epigenetic changes within the cancer cells as well as contributions from cells in the tumor microenvironment. Mouse models have proven to be an important tool for unraveling the complex interactions involved in the metastatic cascade and delineating its many stages. Here, we critically appraise the strengths and weaknesses of the current mouse models and highlight the recent advances that have been made using these models in our understanding of metastasis. We also discuss the use of these models for testing potential therapies and the challenges associated with the translation of these findings into the provision of new and effective treatments for cancer patients.

1 August 2008 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
VBValerie G. Brunton
Valerie G. Brunton
MFMargaret C Frame
Margaret C Frame

1 July 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JMJennifer P Morton
Jennifer P Morton
SKSaadia A. Karim
Saadia A. Karim
KGKathryn Graham
Kathryn Graham
PTPaul Timpson
Paul Timpson
NJNigel Jamieson
Nigel Jamieson
VBValerie G. Brunton
Valerie G. Brunton

1 June 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
PHPriya Hari
Priya Hari
FMFraser R. Millar
Fraser R. Millar
NTNuria Tarrats
Nuria Tarrats
JBJodie Birch
Jodie Birch
AQAndrea Quintanilla
Andrea Quintanilla
JAJuan Carlos Acosta
Juan Carlos Acosta
Cellular senescence is a stress response program characterized by a robust cell cycle arrest and the induction of a proinflammatory senescence-associated secretory phenotype (SASP) that is triggered through an unknown mechanism. Here, we show that, during oncogene-induced senescence (OIS), the Toll-like receptor 2 (TLR2) and its partner TLR10 are key mediators of senescence in vitro and in murine models. TLR2 promotes cell cycle arrest by regulating the tumor suppressors p53-p21CIP1, p16INK4a, and p15INK4b and regulates the SASP through the induction of the acute-phase serum amyloids A1 and A2 (A-SAAs) that, in turn, function as the damage-associated molecular patterns (DAMPs) signaling through TLR2 in OIS. Last, we found evidence that the cGAS-STING cytosolic DNA sensing pathway primes TLR2 and A-SAAs expression in OIS. In summary, we report that innate immune sensing of senescence-associated DAMPs by TLR2 controls the SASP and reinforces the cell cycle arrest program in OIS.

14 November 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MCMarta Canel
Marta Canel
ASAlan Serrels
Alan Serrels
DMDerek Miller
Derek Miller
PTPaul Timpson
Paul Timpson
BSBryan Serrels
Bryan Serrels
VBValerie G. Brunton
Valerie G. Brunton
Most cancer-related deaths are due to the development of metastatic disease, and several new molecularly targeted agents in clinical development have the potential to prevent disease progression. However, it remains difficult to assess the efficacy of antimetastatic agents in the clinical setting, and an increased understanding of how such agents work at different stages of the metastatic cascade is important in guiding their clinical use. We used optical window chambers combined with photobleaching, photoactivation, and photoswitching to quantitatively measure (a) tumor cell movement and proliferation by tracking small groups of cells in the context of the whole tumor, and (b) E-cadherin molecular dynamics in vivo following perturbation of integrin signaling by inhibiting focal adhesion kinase (FAK) and Src. We show that inhibition of Src and FAK suppresses E-cadherin–dependent collective cell movement in a complex three-dimensional tumor environment, and modulates cell-cell adhesion strength and endocytosis in vitro. This shows a novel role for integrin signaling in the regulation of E-cadherin internalization, which is linked to regulation of collective cancer cell movement. This work highlights the power of fluorescent, direct, in vivo imaging approaches in the preclinical evaluation of chemotherapeutic agents, and shows that inhibition of the Src/FAK signaling axis may provide a strategy to prevent tumor cell spread by deregulating E-cadherin–mediated cell-cell adhesions. Cancer Res; 70(22); 9413–22. ©2010 AACR.

12 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJulia M. Houthuijzen
Julia M. Houthuijzen
RBRoebi de Bruijn
Roebi de Bruijn
EBEline van der Burg
Eline van der Burg
ADAnne Paulien Drenth
Anne Paulien Drenth
EWEllen Wientjens
Ellen Wientjens
JJJos Jonkers
Jos Jonkers
Cancer-associated fibroblasts (CAFs) are abundantly present in the microenvironment of virtually all tumors and strongly impact tumor progression. Despite increasing insight into their function and heterogeneity, little is known regarding the origin of CAFs. Understanding the origin of CAF heterogeneity is needed to develop successful CAF-based targeted therapies. Through various transplantation studies in mice, we show that CAFs in both invasive lobular breast cancer and triple-negative breast cancer originate from mammary tissue-resident normal fibroblasts (NFs). Single-cell transcriptomics, in vivo and in vitro studies reveal the transition of CD26+ and CD26- NF populations into inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs), respectively. Functional co-culture experiments show that CD26+ NFs transition into pro-tumorigenic iCAFs which recruit myeloid cells in a CXCL12-dependent manner and enhance tumor cell invasion via matrix-metalloproteinase (MMP) activity. Together, our data suggest that CD26+ and CD26- NFs transform into distinct CAF subpopulations in mouse models of breast cancer.